September 2020

SpyBiotech and Serum Institute of India announce that the first subjects have been dosed in a Phase I/II trial of a novel virus-like particle vaccine targeting COVID-19

News /

Oxford, UK, September 8: SpyBiotech, a company with a novel vaccine platform to target infectious diseases, cancer and chronic diseases, today announces that its partner the Serum Institute of India (SIIPL) has dosed the first subjects in a Phase I/II trial of a novel virus-like particle (VLP) vaccine targeting COVID-19. SpyBiotech has signed an exclusive […]

SpyBiotech and Serum Institute of India announce that the first subjects have been dosed in a Phase I/II trial of a novel virus-like particle vaccine targeting COVID-19 Read More »

Covid-19 vaccine candidates using SpyCatcher/SpyTag to display Spike protein on computationally designed particles and Bacteriophage VLPs

News /

2 recent papers with really interesting results! Click here to read the full paper on computationally designed VLPs. Results: RBD can be efficiently displayed on the mi3 VLP via SpyTag/SpyCatcher RBD-SpyVLP is reactive to monoclonal antibodies isolated from recovered patients RBD-SpyVLP induces a strong ACE2-blocking and neutralising antibody response in mouse models RBD-SpyVLP is highly

Covid-19 vaccine candidates using SpyCatcher/SpyTag to display Spike protein on computationally designed particles and Bacteriophage VLPs Read More »

Scroll to Top